<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Inherited Bone Marrow Failure Syndromes | Bloodü©∏Doctor</title>
    <meta name="description" content="Comprehensive guide to Inherited Aplastic Anaemia and Bone Marrow Failure Syndromes for Haematologists and Trainees">
    <meta name="author" content="Dr Abdul Mannan FRCPath FCPS">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <div class="container">
            <div class="header-content">
                <a href="#" class="logo">Blood<span class="blood-drop">ü©∏</span>Doctor</a>
                <nav class="nav">
                    <button class="nav-toggle" aria-label="Toggle navigation">
                        <span></span><span></span><span></span>
                    </button>
                    <ul class="nav-menu">
                        <li><a href="#overview">Overview</a></li>
                        <li><a href="#fanconi">Fanconi Anaemia</a></li>
                        <li><a href="#dc">Dyskeratosis Congenita</a></li>
                        <li><a href="#sds">SDS</a></li>
                        <li><a href="#dba">DBA</a></li>
                        <li><a href="#cda">CDA</a></li>
                        <li><a href="#neutropenia">Neutropenia</a></li>
                        <li><a href="#diagnosis">Diagnosis</a></li>
                    </ul>
                </nav>
            </div>
        </div>
    </header>

    <!-- Hero Section -->
    <section class="hero">
        <div class="container">
            <div class="hero-content">
                <span class="hero-badge">Chapter 30 | Hoffbrand's Postgraduate Haematology</span>
                <h1>Inherited Aplastic Anaemia & Bone Marrow Failure Syndromes</h1>
                <p class="hero-subtitle">A comprehensive learning guide for haematologists, physicians, and trainees</p>
                <div class="hero-stats">
                    <div class="stat">
                        <span class="stat-number">20-30%</span>
                        <span class="stat-label">of AA patients have inherited BMF</span>
                    </div>
                    <div class="stat">
                        <span class="stat-number">22+</span>
                        <span class="stat-label">FA genes identified</span>
                    </div>
                    <div class="stat">
                        <span class="stat-number">20+</span>
                        <span class="stat-label">DC genes identified</span>
                    </div>
                </div>
                <a href="#overview" class="btn btn-primary">Start Learning</a>
            </div>
        </div>
    </section>

    <!-- Quick Navigation Cards -->
    <section class="quick-nav">
        <div class="container">
            <div class="nav-cards">
                <a href="#fanconi" class="nav-card">
                    <div class="nav-card-icon">üß¨</div>
                    <h3>Fanconi Anaemia</h3>
                    <p>DNA repair defects, 22 genes, malignancy risk</p>
                </a>
                <a href="#dc" class="nav-card">
                    <div class="nav-card-icon">üî¨</div>
                    <h3>Dyskeratosis Congenita</h3>
                    <p>Telomere biology disorders, mucocutaneous triad</p>
                </a>
                <a href="#sds" class="nav-card">
                    <div class="nav-card-icon">ü¶¥</div>
                    <h3>Shwachman-Diamond</h3>
                    <p>Ribosome biogenesis, pancreatic insufficiency</p>
                </a>
                <a href="#dba" class="nav-card">
                    <div class="nav-card-icon">üî¥</div>
                    <h3>Diamond-Blackfan</h3>
                    <p>Pure red cell aplasia, ribosomal proteins</p>
                </a>
                <a href="#cda" class="nav-card">
                    <div class="nav-card-icon">üíâ</div>
                    <h3>CDA</h3>
                    <p>Congenital dyserythropoietic anaemias</p>
                </a>
                <a href="#neutropenia" class="nav-card">
                    <div class="nav-card-icon">‚ö™</div>
                    <h3>Congenital Neutropenia</h3>
                    <p>SCN, Kostmann syndrome, cyclic neutropenia</p>
                </a>
            </div>
        </div>
    </section>

    <!-- Overview Section -->
    <section id="overview" class="section">
        <div class="container">
            <h2 class="section-title">Overview of Inherited BMF Syndromes</h2>

            <div class="callout callout-key">
                <div class="callout-icon">üéØ</div>
                <div class="callout-content">
                    <h4>Key Concept</h4>
                    <p>Inherited BMF syndromes are constitutional/genetic disorders characterized by aplastic anaemia/bone marrow failure, usually associated with somatic abnormalities. They represent <strong>20-30% of patients presenting with AA</strong>.</p>
                </div>
            </div>

            <div class="content-grid">
                <div class="content-card">
                    <h3>Clinical Presentation Patterns</h3>
                    <ul class="feature-list">
                        <li>May present at birth or at variable time thereafter</li>
                        <li>Can present in adulthood</li>
                        <li>May involve all lineages or single lineage initially</li>
                        <li>Single cytopenia may progress to pancytopenia</li>
                        <li>~1/3 of patients have NO physical abnormalities</li>
                    </ul>
                </div>
                <div class="content-card">
                    <h3>Why Recognition Matters</h3>
                    <ul class="feature-list">
                        <li>Impacts understanding of "idiopathic" AA pathophysiology</li>
                        <li>Guides appropriate HSCT conditioning protocols</li>
                        <li>Determines surveillance for malignancy</li>
                        <li>Enables genetic counselling for families</li>
                        <li>May present with AA/BMF as initial manifestation</li>
                    </ul>
                </div>
            </div>

            <!-- Inherited BMF Table -->
            <h3 class="subsection-title">Table 30.1: The Inherited BMF Syndromes</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Category</th>
                            <th>Syndromes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Pancytopenia</strong><br>(global haemopoietic defect)</td>
                            <td>
                                <ul>
                                    <li>Fanconi anaemia</li>
                                    <li>Dyskeratosis congenita</li>
                                    <li>Shwachman-Diamond syndrome</li>
                                    <li>Reticular dysgenesis</li>
                                    <li>Pearson syndrome</li>
                                    <li>Familial aplastic anaemia (autosomal and X-linked)</li>
                                    <li>Myelodysplasia</li>
                                    <li>Non-haematological syndromes (Down, Dubowitz)</li>
                                </ul>
                            </td>
                        </tr>
                        <tr>
                            <td><strong>Single Cytopenia - Anaemia</strong></td>
                            <td>
                                <ul>
                                    <li>Diamond-Blackfan anaemia</li>
                                    <li>Congenital dyserythropoietic anaemia</li>
                                </ul>
                            </td>
                        </tr>
                        <tr>
                            <td><strong>Single Cytopenia - Neutropenia</strong></td>
                            <td>
                                <ul>
                                    <li>Severe congenital neutropenia (Kostmann syndrome)</li>
                                </ul>
                            </td>
                        </tr>
                        <tr>
                            <td><strong>Single Cytopenia - Thrombocytopenia</strong></td>
                            <td>
                                <ul>
                                    <li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li>
                                    <li>Amegakaryocytic thrombocytopenia with absent radii (TAR)</li>
                                </ul>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <!-- Comparison Table -->
            <h3 class="subsection-title">Table 30.2: Characteristics Comparison of BMF Syndromes</h3>
            <div class="table-responsive">
                <table class="data-table comparison-table">
                    <thead>
                        <tr>
                            <th>Feature</th>
                            <th>FA</th>
                            <th>DC</th>
                            <th>SDS</th>
                            <th>DBA</th>
                            <th>CDA</th>
                            <th>TAR+CAMT</th>
                            <th>SCN</th>
                            <th>IAA</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Inheritance</strong></td>
                            <td>AR, XLR</td>
                            <td>XLR, AR, AD</td>
                            <td>AR</td>
                            <td>AD, XLR</td>
                            <td>AR, AD</td>
                            <td>AR</td>
                            <td>AD, AR</td>
                            <td>?None</td>
                        </tr>
                        <tr>
                            <td><strong>Somatic abnormalities</strong></td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>Rare</td>
                            <td>Yes</td>
                            <td>Rare</td>
                            <td>?None</td>
                        </tr>
                        <tr>
                            <td><strong>Bone marrow failure</strong></td>
                            <td>AA (>90%)</td>
                            <td>AA (~80%)</td>
                            <td>AA (20%)</td>
                            <td>RCA</td>
                            <td>Eryth</td>
                            <td>Megs</td>
                            <td>Neutropenia</td>
                            <td>Yes (100%)</td>
                        </tr>
                        <tr>
                            <td><strong>Short telomeres</strong></td>
                            <td>Yes*</td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>?No</td>
                            <td>?No</td>
                            <td>?</td>
                            <td>Yes</td>
                            <td>No</td>
                        </tr>
                        <tr>
                            <td><strong>Malignancy risk</strong></td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>?No</td>
                            <td>?</td>
                            <td>?</td>
                            <td>Yes</td>
                            <td>?</td>
                        </tr>
                        <tr>
                            <td><strong>Chromosome instability</strong></td>
                            <td>Yes</td>
                            <td>Yes</td>
                            <td>?</td>
                            <td>?</td>
                            <td>?</td>
                            <td>?</td>
                            <td>Yes</td>
                            <td>?</td>
                        </tr>
                        <tr>
                            <td><strong>Genes identified</strong></td>
                            <td>22</td>
                            <td>20</td>
                            <td>4</td>
                            <td>21</td>
                            <td>5</td>
                            <td>4</td>
                            <td>7+</td>
                            <td>25+</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p class="table-note">*Telomeres are usually very short in DC, short in FA and SDS. AR=autosomal recessive; AD=autosomal dominant; XLR=X-linked recessive; AA=aplastic anaemia; RCA=red cell aplasia; Eryth=ineffective erythropoiesis; Megs=low megakaryocytes</p>
        </div>
    </section>

    <!-- Fanconi Anaemia Section -->
    <section id="fanconi" class="section section-alt">
        <div class="container">
            <h2 class="section-title">Fanconi Anaemia (FA)</h2>

            <div class="callout callout-history">
                <div class="callout-icon">üìú</div>
                <div class="callout-content">
                    <h4>Historical Note</h4>
                    <p>First described by Guido Fanconi in 1927. FA is an autosomal recessive disorder (X-linked in rare subset) with progressive BMF and increased predisposition to malignancy, especially AML.</p>
                </div>
            </div>

            <div class="two-column">
                <div class="column">
                    <div class="info-box">
                        <h3>Clinical Features</h3>
                        <ul class="check-list">
                            <li>Progressive bone marrow failure</li>
                            <li>Increased malignancy risk (AML, solid tumours)</li>
                            <li>Somatic abnormalities (~70% of patients)</li>
                            <li>~1/3 have NO physical abnormalities</li>
                            <li>Median survival: 24 years (improving with clinical care)</li>
                        </ul>
                    </div>

                    <div class="info-box">
                        <h3>Natural History</h3>
                        <ul class="timeline">
                            <li><span class="time">Birth</span> Blood count usually normal</li>
                            <li><span class="time">5-10 years</span> Pancytopenia develops (median age 7)</li>
                            <li><span class="time">~40 years</span> ~90% develop BMF</li>
                            <li><span class="time">~40 years</span> 33% cumulative haematological malignancy</li>
                            <li><span class="time">~40 years</span> 28% cumulative solid tumours</li>
                        </ul>
                    </div>
                </div>
                <div class="column">
                    <div class="high-yield">
                        <h3>üéØ High-Yield: Somatic Abnormalities in FA</h3>
                        <div class="percentage-bar">
                            <div class="bar-item">
                                <span class="bar-label">Skeletal (radial ray, vertebral, scoliosis)</span>
                                <div class="bar"><div class="bar-fill" style="width: 71%"></div></div>
                                <span class="bar-value">71%</span>
                            </div>
                            <div class="bar-item">
                                <span class="bar-label">Skin pigmentation (cafe-au-lait, hypo/hyper)</span>
                                <div class="bar"><div class="bar-fill" style="width: 64%"></div></div>
                                <span class="bar-value">64%</span>
                            </div>
                            <div class="bar-item">
                                <span class="bar-label">Short stature</span>
                                <div class="bar"><div class="bar-fill" style="width: 63%"></div></div>
                                <span class="bar-value">63%</span>
                            </div>
                            <div class="bar-item">
                                <span class="bar-label">Eyes (microphthalmia)</span>
                                <div class="bar"><div class="bar-fill" style="width: 38%"></div></div>
                                <span class="bar-value">38%</span>
                            </div>
                            <div class="bar-item">
                                <span class="bar-label">Renal/urinary tract</span>
                                <div class="bar"><div class="bar-fill" style="width: 34%"></div></div>
                                <span class="bar-value">34%</span>
                            </div>
                            <div class="bar-item">
                                <span class="bar-label">No abnormalities</span>
                                <div class="bar"><div class="bar-fill bar-warning" style="width: 30%"></div></div>
                                <span class="bar-value">30%</span>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- FA Genetics Table -->
            <h3 class="subsection-title">Table 30.4: FA Complementation Groups/Genetic Subtypes</h3>
            <div class="callout callout-info">
                <div class="callout-icon">üí°</div>
                <div class="callout-content">
                    <h4>Key Point</h4>
                    <p>FA subtypes A, C, and G account for the majority of FA patients. Many FA genes encode proteins with important roles in DNA repair.</p>
                </div>
            </div>

            <div class="table-responsive">
                <table class="data-table genetics-table">
                    <thead>
                        <tr>
                            <th>Group/Gene</th>
                            <th>% of Patients</th>
                            <th>Chromosome</th>
                            <th>Exons</th>
                            <th>Clinical Notes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="highlight-row">
                            <td><strong>A (FANCA)</strong></td>
                            <td>65%</td>
                            <td>16q24.3</td>
                            <td>44</td>
                            <td>Most common subtype</td>
                        </tr>
                        <tr>
                            <td>B (FANCB)</td>
                            <td>&lt;1%</td>
                            <td>Xp22.2</td>
                            <td>17</td>
                            <td>X-linked</td>
                        </tr>
                        <tr class="highlight-row">
                            <td><strong>C (FANCC)</strong></td>
                            <td>12%</td>
                            <td>9q22.3</td>
                            <td>22</td>
                            <td>Second most common</td>
                        </tr>
                        <tr>
                            <td>D1 (FANCD1/BRCA2)</td>
                            <td>&lt;1%</td>
                            <td>13q13.1</td>
                            <td>27</td>
                            <td>High childhood cancer risk (Wilm's, medulloblastoma)</td>
                        </tr>
                        <tr>
                            <td>D2 (FANCD2)</td>
                            <td>&lt;1%</td>
                            <td>3p25.3</td>
                            <td>45</td>
                            <td>Core complex target</td>
                        </tr>
                        <tr>
                            <td>E (FANCE)</td>
                            <td>4%</td>
                            <td>6p21.31</td>
                            <td>10</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>F (FANCF)</td>
                            <td>4%</td>
                            <td>11p14.3</td>
                            <td>1</td>
                            <td></td>
                        </tr>
                        <tr class="highlight-row">
                            <td><strong>G (FANCG)</strong></td>
                            <td>12%</td>
                            <td>9p13.3</td>
                            <td>14</td>
                            <td>Third most common</td>
                        </tr>
                        <tr>
                            <td>I (FANCI)</td>
                            <td>&lt;1%</td>
                            <td>15q26.1</td>
                            <td>38</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>J (FANCJ/BRIP1)</td>
                            <td>&lt;5%</td>
                            <td>17q23.2</td>
                            <td>25</td>
                            <td>Breast cancer risk gene</td>
                        </tr>
                        <tr>
                            <td>L (FANCL)</td>
                            <td>&lt;1%</td>
                            <td>2p16.1</td>
                            <td>14</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>N (FANCN/PALB2)</td>
                            <td>&lt;1%</td>
                            <td>16p12.2</td>
                            <td>14</td>
                            <td>High childhood cancer risk, breast cancer</td>
                        </tr>
                        <tr>
                            <td>Q (FANCQ/ERCC4)</td>
                            <td>&lt;1%</td>
                            <td>16p13.12</td>
                            <td>13</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>R (FANCR/RAD51)</td>
                            <td>&lt;1%</td>
                            <td>15q15.1</td>
                            <td>13</td>
                            <td>Heterozygous variants</td>
                        </tr>
                        <tr>
                            <td>S (FANCS/BRCA1)</td>
                            <td>&lt;1%</td>
                            <td>17q21.31</td>
                            <td>24</td>
                            <td>Breast/ovarian cancer gene</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <!-- FA-BRCA Pathway Diagram -->
            <h3 class="subsection-title">The FA-BRCA DNA Repair Pathway</h3>
            <div class="pathway-diagram">
                <div class="pathway-container">
                    <div class="pathway-box pathway-trigger">
                        <h4>Triggers</h4>
                        <ul>
                            <li>DNA crosslinks</li>
                            <li>Replication fork arrest</li>
                            <li>Oxidative stress</li>
                            <li>Environmental factors</li>
                        </ul>
                    </div>
                    <div class="pathway-arrow">‚Üí</div>
                    <div class="pathway-box pathway-core">
                        <h4>FA Core Complex</h4>
                        <p class="pathway-subtitle">8 FA proteins</p>
                        <div class="gene-tags">
                            <span class="gene-tag">FANCA</span>
                            <span class="gene-tag">FANCB</span>
                            <span class="gene-tag">FANCC</span>
                            <span class="gene-tag">FANCE</span>
                            <span class="gene-tag">FANCF</span>
                            <span class="gene-tag">FANCG</span>
                            <span class="gene-tag">FANCL</span>
                            <span class="gene-tag">FANCM</span>
                        </div>
                    </div>
                    <div class="pathway-arrow">‚Üí</div>
                    <div class="pathway-box pathway-id">
                        <h4>I-D2 Complex</h4>
                        <p>Monoubiquitination</p>
                        <div class="gene-tags">
                            <span class="gene-tag highlight">FANCI</span>
                            <span class="gene-tag highlight">FANCD2-Ub</span>
                        </div>
                    </div>
                    <div class="pathway-arrow">‚Üí</div>
                    <div class="pathway-box pathway-repair">
                        <h4>DNA Repair Foci</h4>
                        <div class="gene-tags">
                            <span class="gene-tag danger">BRCA2</span>
                            <span class="gene-tag danger">BRCA1</span>
                            <span class="gene-tag danger">RAD51</span>
                            <span class="gene-tag danger">PALB2</span>
                            <span class="gene-tag danger">SLX4</span>
                        </div>
                    </div>
                </div>
                <div class="pathway-regulator">
                    <span class="regulator-label">ATR Kinase</span>
                    <span class="regulator-arrow">‚Üì</span>
                    <span class="regulator-target">Activates pathway via FANCD2/FANCI phosphorylation</span>
                </div>
            </div>

            <div class="callout callout-exam">
                <div class="callout-icon">üìù</div>
                <div class="callout-content">
                    <h4>Exam Pearl: FA Cell Phenotype</h4>
                    <p>FA cells show <strong>increased chromosomal breakage</strong> after exposure to DNA cross-linking agents (DEB/MMC). This is the basis of the diagnostic test - the DEB/MMC-induced chromosomal breakage test.</p>
                </div>
            </div>

            <!-- FA Diagnosis and Treatment -->
            <div class="two-column">
                <div class="column">
                    <div class="algorithm-box">
                        <h3>Diagnostic Approach</h3>
                        <div class="algorithm-steps">
                            <div class="step">
                                <span class="step-number">1</span>
                                <div class="step-content">
                                    <strong>Clinical Suspicion</strong>
                                    <p>BMF + somatic abnormalities OR early-onset AA</p>
                                </div>
                            </div>
                            <div class="step">
                                <span class="step-number">2</span>
                                <div class="step-content">
                                    <strong>DEB/MMC Chromosome Breakage Test</strong>
                                    <p>Gold standard screening test</p>
                                </div>
                            </div>
                            <div class="step">
                                <span class="step-number">3</span>
                                <div class="step-content">
                                    <strong>Genetic Testing</strong>
                                    <p>NGS panel for FA genes (FANCA-FANCW)</p>
                                </div>
                            </div>
                            <div class="step">
                                <span class="step-number">4</span>
                                <div class="step-content">
                                    <strong>Family Screening</strong>
                                    <p>Siblings for potential HSCT donors</p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="column">
                    <div class="treatment-box">
                        <h3>Treatment Principles</h3>
                        <div class="treatment-section">
                            <h4>üéØ Curative: HSCT</h4>
                            <ul>
                                <li>Only curative treatment for BMF</li>
                                <li><strong>Modified conditioning required</strong> - FA patients hypersensitive to cyclophosphamide and radiation</li>
                                <li>Low-dose cyclophosphamide (20-40 mg/kg)</li>
                                <li>4.5-6 Gy thoracoabdominal irradiation</li>
                                <li>HLA-identical sibling: ~70% 2-year survival</li>
                                <li>Unrelated donor: 20-40% survival</li>
                            </ul>
                        </div>
                        <div class="treatment-section">
                            <h4>üìã Supportive Care</h4>
                            <ul>
                                <li>Androgens (oxymetholone, danazol) - 50-70% response</li>
                                <li>Blood product support</li>
                                <li>Surveillance for malignancy</li>
                                <li>Gene therapy trials (FA-A patients)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="callout callout-warning">
                <div class="callout-icon">‚ö†Ô∏è</div>
                <div class="callout-content">
                    <h4>Critical Warning: Post-HSCT Malignancy</h4>
                    <p>FA patients who undergo HSCT have a <strong>higher incidence of non-haematological malignancies</strong> (particularly head and neck SCC), usually 8-10 years post-transplant. Lifelong surveillance is essential.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Dyskeratosis Congenita Section -->
    <section id="dc" class="section">
        <div class="container">
            <h2 class="section-title">Dyskeratosis Congenita (DC)</h2>

            <div class="callout callout-key">
                <div class="callout-icon">üîë</div>
                <div class="callout-content">
                    <h4>Core Concept: Telomere Biology Disorder</h4>
                    <p>DC is characterized by the <strong>mucocutaneous triad</strong> of abnormal skin pigmentation, nail dystrophy, and mucosal leucoplakia. The underlying cause is <strong>defective telomere maintenance</strong>.</p>
                </div>
            </div>

            <div class="triad-display">
                <h3>The Classical Mucocutaneous Triad</h3>
                <div class="triad-cards">
                    <div class="triad-card">
                        <div class="triad-icon">üé®</div>
                        <h4>Abnormal Skin Pigmentation</h4>
                        <p class="percentage">89%</p>
                        <p>Reticulated hyper/hypopigmentation, typically on neck and upper trunk</p>
                    </div>
                    <div class="triad-card">
                        <div class="triad-icon">üíÖ</div>
                        <h4>Nail Dystrophy</h4>
                        <p class="percentage">88%</p>
                        <p>Ridging, splitting, poor growth; may progress to complete loss</p>
                    </div>
                    <div class="triad-card">
                        <div class="triad-icon">üëÖ</div>
                        <h4>Oral Leucoplakia</h4>
                        <p class="percentage">78%</p>
                        <p>White patches on tongue and buccal mucosa; premalignant</p>
                    </div>
                </div>
            </div>

            <!-- DC Somatic Abnormalities -->
            <h3 class="subsection-title">Table 30.5: Somatic Abnormalities in DC</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Abnormality</th>
                            <th>% of Patients</th>
                            <th>Clinical Significance</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr><td>Abnormal skin pigmentation</td><td>89%</td><td>Often first sign</td></tr>
                        <tr><td>Nail dystrophy</td><td>88%</td><td>Progressive</td></tr>
                        <tr class="highlight-row"><td><strong>BMF</strong></td><td><strong>85.5%</strong></td><td><strong>Main cause of mortality</strong></td></tr>
                        <tr><td>Leucoplakia</td><td>78%</td><td>Premalignant</td></tr>
                        <tr><td>Epiphora (excessive tearing)</td><td>30.5%</td><td>Lacrimal duct stenosis</td></tr>
                        <tr><td>Learning difficulties</td><td>25.4%</td><td>Variable severity</td></tr>
                        <tr><td>Pulmonary disease</td><td>20.3%</td><td>Fibrosis - major cause of death</td></tr>
                        <tr><td>Short stature</td><td>19.5%</td><td></td></tr>
                        <tr><td>Malignancy</td><td>15.5%</td><td>~10-15% mortality</td></tr>
                        <tr><td>Liver disease</td><td>7.3%</td><td>Cirrhosis, fibrosis</td></tr>
                    </tbody>
                </table>
            </div>

            <div class="callout callout-clinical">
                <div class="callout-icon">üè•</div>
                <div class="callout-content">
                    <h4>Clinical Diagnostic Criteria</h4>
                    <p>Minimal criteria: <strong>At least 2 of 4 major features</strong> (abnormal skin pigmentation, nail dystrophy, leucoplakia, BMF) <strong>PLUS 2 or more</strong> of other somatic features known to occur in DC.</p>
                </div>
            </div>

            <!-- Causes of Death in DC -->
            <div class="mortality-box">
                <h3>Causes of Mortality in DC</h3>
                <div class="mortality-chart">
                    <div class="mortality-item">
                        <div class="mortality-bar" style="width: 70%"></div>
                        <span class="mortality-label">BMF/Immunodeficiency</span>
                        <span class="mortality-value">~60-70%</span>
                    </div>
                    <div class="mortality-item">
                        <div class="mortality-bar" style="width: 15%"></div>
                        <span class="mortality-label">Pulmonary Complications</span>
                        <span class="mortality-value">~10-15%</span>
                    </div>
                    <div class="mortality-item">
                        <div class="mortality-bar" style="width: 15%"></div>
                        <span class="mortality-label">Malignancy</span>
                        <span class="mortality-value">~10%</span>
                    </div>
                </div>
            </div>

            <!-- DC Genetics -->
            <h3 class="subsection-title">Table 30.6: Genetic Subtypes of DC</h3>
            <div class="table-responsive">
                <table class="data-table genetics-table">
                    <thead>
                        <tr>
                            <th>DC Subtype</th>
                            <th>% of Patients</th>
                            <th>Chromosome</th>
                            <th>Gene/Protein</th>
                            <th>Function</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="subtype-header">
                            <td colspan="5"><strong>X-linked Recessive</strong></td>
                        </tr>
                        <tr class="highlight-row">
                            <td>Classical X-linked DC</td>
                            <td>25%</td>
                            <td>Xq28</td>
                            <td>DKC1/Dyskerin</td>
                            <td>Telomerase complex stability</td>
                        </tr>
                        <tr class="subtype-header">
                            <td colspan="5"><strong>Autosomal Dominant</strong></td>
                        </tr>
                        <tr>
                            <td>AD-DC</td>
                            <td>12%</td>
                            <td>14q11</td>
                            <td>TIN2</td>
                            <td>Shelterin complex</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>AD-DC</td>
                            <td>5%</td>
                            <td>3q26.2</td>
                            <td>TERC</td>
                            <td>Telomerase RNA component</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>AD-DC</td>
                            <td>3%</td>
                            <td>5p15.33</td>
                            <td>TERT</td>
                            <td>Telomerase reverse transcriptase</td>
                        </tr>
                        <tr>
                            <td>AD-DC</td>
                            <td>&lt;1%</td>
                            <td>17p13.3</td>
                            <td>RPA1</td>
                            <td>DNA replication</td>
                        </tr>
                        <tr class="subtype-header">
                            <td colspan="5"><strong>Autosomal Recessive</strong></td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>2%</td>
                            <td>16q21</td>
                            <td>USB1</td>
                            <td>RNA processing</td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>2%</td>
                            <td>20q13.3</td>
                            <td>RTEL1</td>
                            <td>Telomere maintenance</td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>2%</td>
                            <td>16p13.12</td>
                            <td>PARN</td>
                            <td>Telomerase maturation</td></tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>&lt;1%</td>
                            <td>15q14</td>
                            <td>NOP10</td>
                            <td>H/ACA RNP complex</td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>&lt;1%</td>
                            <td>5p15.33</td>
                            <td>TERT</td>
                            <td>Biallelic variants</td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>&lt;1%</td>
                            <td>5q35.3</td>
                            <td>NHP2</td>
                            <td>H/ACA RNP complex</td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>&lt;1%</td>
                            <td>17p13.1</td>
                            <td>WRAP53/TCAB1</td>
                            <td>Telomerase trafficking</td>
                        </tr>
                        <tr>
                            <td>AR-DC</td>
                            <td>&lt;1%</td>
                            <td>17p13.1</td>
                            <td>CTC1</td>
                            <td>Telomere capping</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <!-- Telomere Biology Diagram -->
            <h3 class="subsection-title">Telomere Maintenance & Ribosome Biogenesis Pathways</h3>
            <div class="diagram-container">
                <div class="telomere-diagram">
                    <div class="diagram-section">
                        <h4>Telomere Maintenance</h4>
                        <div class="diagram-box telomere-box">
                            <div class="telomere-component">
                                <span class="component-name">Shelterin Complex</span>
                                <div class="gene-tags small">
                                    <span class="gene-tag">TIN2</span>
                                    <span class="gene-tag">ACD</span>
                                    <span class="gene-tag">POT1</span>
                                    <span class="gene-tag">RTEL1</span>
                                </div>
                            </div>
                            <div class="telomere-component">
                                <span class="component-name">Telomerase Complex</span>
                                <div class="gene-tags small">
                                    <span class="gene-tag highlight">TERT</span>
                                    <span class="gene-tag highlight">TERC</span>
                                    <span class="gene-tag">DKC1</span>
                                    <span class="gene-tag">NOP10</span>
                                    <span class="gene-tag">NHP2</span>
                                </div>
                            </div>
                            <div class="telomere-component">
                                <span class="component-name">Telomere Capping</span>
                                <div class="gene-tags small">
                                    <span class="gene-tag">CTC1</span>
                                    <span class="gene-tag">TCAB1</span>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="diagram-section">
                        <h4>Ribosome Biogenesis</h4>
                        <div class="diagram-box ribosome-box">
                            <div class="ribosome-component">
                                <span class="component-name">rRNA Processing</span>
                                <div class="gene-tags small">
                                    <span class="gene-tag">NAF1</span>
                                    <span class="gene-tag">PARN</span>
                                </div>
                            </div>
                            <div class="ribosome-component">
                                <span class="component-name">rRNA Modification</span>
                                <div class="gene-tags small">
                                    <span class="gene-tag">DKC1</span>
                                    <span class="gene-tag">NPM1</span>
                                </div>
                            </div>
                            <div class="ribosome-component">
                                <span class="component-name">mRNA Splicing</span>
                                <div class="gene-tags small">
                                    <span class="gene-tag">USB1</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="callout callout-exam">
                <div class="callout-icon">üìù</div>
                <div class="callout-content">
                    <h4>Exam Pearl: Hoyeraal-Hreidarsson Syndrome</h4>
                    <p>HH syndrome is a <strong>severe variant of DC</strong> characterized by intrauterine growth restriction, microcephaly, cerebellar hypoplasia, AA, and immunodeficiency. Often caused by <em>DKC1</em> variants but also other genes.</p>
                </div>
            </div>

            <!-- DC Treatment -->
            <div class="treatment-box full-width">
                <h3>Treatment of DC</h3>
                <div class="treatment-grid">
                    <div class="treatment-item">
                        <h4>ü©∏ Supportive Care</h4>
                        <ul>
                            <li>Oxymetholone - ~2/3 respond</li>
                            <li>Dose: 0.25 mg to 2-5 mg/kg/day</li>
                            <li>Monitor for liver toxicity</li>
                            <li>Danazol - alternative option</li>
                            <li>Response can last years across all lineages</li>
                        </ul>
                    </div>
                    <div class="treatment-item">
                        <h4>üè• HSCT</h4>
                        <ul>
                            <li>Only long-term cure for haemopoietic abnormalities</li>
                            <li>Significant mortality (pulmonary complications)</li>
                            <li>Non-myeloablative fludarabine-based protocols preferred</li>
                            <li>Lower toxicity, fewer complications</li>
                            <li>Does NOT prevent pulmonary/hepatic complications</li>
                        </ul>
                    </div>
                    <div class="treatment-item">
                        <h4>üî¨ Emerging Therapies</h4>
                        <ul>
                            <li>PAPD5 inhibitors - correct telomere defect in vitro</li>
                            <li>Potential future treatment option</li>
                            <li>Gene therapy under investigation</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="callout callout-warning">
                <div class="callout-icon">‚ö†Ô∏è</div>
                <div class="callout-content">
                    <h4>Important: TERC/TERT Variants Beyond DC</h4>
                    <p>Heterozygous <em>TERC</em> and <em>TERT</em> variants are risk factors for some cases of <strong>"idiopathic" AA</strong> and have been identified in patients with <strong>MDS</strong>. This highlights the overlap between inherited and acquired BMF.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Shwachman-Diamond Syndrome Section -->
    <section id="sds" class="section section-alt">
        <div class="container">
            <h2 class="section-title">Shwachman-Diamond Syndrome (SDS)</h2>

            <div class="callout callout-key">
                <div class="callout-icon">üîë</div>
                <div class="callout-content">
                    <h4>Key Features</h4>
                    <p>SDS is characterized by <strong>exocrine pancreatic insufficiency (100%)</strong>, <strong>BMF (100%)</strong>, and <strong>skeletal abnormalities</strong>. It's a disorder of <strong>ribosome biogenesis</strong>.</p>
                </div>
            </div>

            <div class="two-column">
                <div class="column">
                    <div class="info-box">
                        <h3>Clinical Features</h3>
                        <ul class="check-list">
                            <li><strong>Pancreatic insufficiency</strong> - malabsorption, failure to thrive (may improve with age)</li>
                            <li><strong>BMF</strong> - neutropenia most common (~60%), other cytopenias (~20% pancytopenia)</li>
                            <li><strong>Short stature</strong> (~70%)</li>
                            <li>Skeletal abnormalities</li>
                            <li>Metaphyseal dysostosis on X-ray (~60%)</li>
                            <li>Hepatomegaly, rib/thoracic cage abnormalities</li>
                        </ul>
                    </div>
                </div>
                <div class="column">
                    <div class="info-box warning-box">
                        <h3>Haematological Abnormalities</h3>
                        <ul class="check-list">
                            <li><strong>Neutropenia</strong> - ~60% (intermittent or persistent)</li>
                            <li><strong>Pancytopenia</strong> - ~20%</li>
                            <li><strong>MDS/AML</strong> - ~25% by 40 years</li>
                            <li>Often with complex karyotypes</li>
                            <li>Poor response to conventional chemotherapy</li>
                            <li>Only HSCT is curative for leukaemia</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- SDS Genetics -->
            <h3 class="subsection-title">Table 30.7: Genetic Subtypes of SDS</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>SDS Subtype</th>
                            <th>% of Patients</th>
                            <th>Chromosome</th>
                            <th>Gene</th>
                            <th>Exons</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="highlight-row">
                            <td><strong>Classical AR</strong></td>
                            <td>>90%</td>
                            <td>7q11.21</td>
                            <td>SBDS</td>
                            <td>5</td>
                        </tr>
                        <tr>
                            <td>SDS-like AR</td>
                            <td>&lt;2%</td>
                            <td>5p13.2</td>
                            <td>DNAJC21</td>
                            <td>14</td>
                        </tr>
                        <tr>
                            <td>AR</td>
                            <td>&lt;2%</td>
                            <td>15q25.2</td>
                            <td>EFL1</td>
                            <td>22</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>&lt;2%</td>
                            <td>14q13.2</td>
                            <td>SRP54</td>
                            <td>17</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="callout callout-info">
                <div class="callout-icon">üí°</div>
                <div class="callout-content">
                    <h4>Molecular Biology</h4>
                    <p>The <em>SBDS</em> gene on 7q11.21 encodes a protein important in the <strong>maturation of the 60S ribosomal subunit</strong>. SDS is principally a disorder of <strong>ribosome biogenesis</strong>, linking it mechanistically to DBA.</p>
                </div>
            </div>

            <!-- SDS vs Pearson Syndrome -->
            <div class="comparison-box">
                <h3>Differential Diagnosis: SDS vs Pearson Syndrome</h3>
                <div class="comparison-grid">
                    <div class="comparison-item">
                        <h4>Shwachman-Diamond</h4>
                        <ul>
                            <li>Neutropenia > anaemia</li>
                            <li>No ringed sideroblasts</li>
                            <li>Normal mitochondrial DNA</li>
                            <li>Metaphyseal dysostosis</li>
                            <li>Better prognosis</li>
                        </ul>
                    </div>
                    <div class="comparison-item">
                        <h4>Pearson Syndrome</h4>
                        <ul>
                            <li>Anaemia > neutropenia</li>
                            <li>Ringed sideroblasts present</li>
                            <li>Mitochondrial DNA deletions</li>
                            <li>Liver dysfunction, acidosis</li>
                            <li>Worse prognosis (death by age 5)</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- SDS Treatment -->
            <div class="treatment-box">
                <h3>Treatment of SDS</h3>
                <div class="treatment-grid">
                    <div class="treatment-item">
                        <h4>üçΩÔ∏è Pancreatic Insufficiency</h4>
                        <p>Oral pancreatic enzyme replacement</p>
                    </div>
                    <div class="treatment-item">
                        <h4>üíâ Neutropenia</h4>
                        <p>G-CSF may improve neutrophil counts</p>
                    </div>
                    <div class="treatment-item">
                        <h4>üè• Leukaemia</h4>
                        <p>Allogeneic HSCT with fludarabine-based conditioning</p>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- Diamond-Blackfan Anaemia Section -->
    <section id="dba" class="section">
        <div class="container">
            <h2 class="section-title">Diamond-Blackfan Anaemia (DBA)</h2>

            <div class="callout callout-history">
                <div class="callout-icon">üìú</div>
                <div class="callout-content">
                    <h4>Historical Note</h4>
                    <p>Red cell aplasia was first reported by Josephs in 1936. Diamond reported on four children with hypoplastic anaemia in 1938. This is now recognized as DBA or congenital pure red cell aplasia.</p>
                </div>
            </div>

            <div class="info-box highlight-box">
                <h3>Diagnostic Criteria for DBA</h3>
                <ol class="numbered-list">
                    <li>Normochromic, usually macrocytic anaemia (occasionally normocytic)</li>
                    <li>Developing in early childhood</li>
                    <li>Reticulocytopenia</li>
                    <li>Normocellular BM with <strong>selective deficiency of erythroid precursors (&lt;5%)</strong></li>
                    <li>Normal or slightly decreased leukocyte counts</li>
                </ol>
            </div>

            <div class="two-column">
                <div class="column">
                    <div class="info-box">
                        <h3>Clinical Features</h3>
                        <ul class="check-list">
                            <li>Presents in early infancy (median 8 weeks)</li>
                            <li>93% present in first year of life</li>
                            <li>Pallor, failure to thrive</li>
                            <li>47% have somatic abnormalities</li>
                            <li>Craniofacial (50%), thumb malformations (38%)</li>
                            <li>Cardiac (30%), genitourinary (39%)</li>
                        </ul>
                    </div>
                    <div class="stats-box">
                        <h4>DBA Registry Data (DBAR)</h4>
                        <div class="stat-grid">
                            <div class="stat-item">
                                <span class="stat-value">5</span>
                                <span class="stat-label">per million live births</span>
                            </div>
                            <div class="stat-item">
                                <span class="stat-value">79%</span>
                                <span class="stat-label">Initially steroid responsive</span>
                            </div>
                            <div class="stat-item">
                                <span class="stat-value">17%</span>
                                <span class="stat-label">Non-responsive</span>
                            </div>
                            <div class="stat-item">
                                <span class="stat-value">4%</span>
                                <span class="stat-label">Never treated with steroids</span>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="column">
                    <div class="high-yield">
                        <h3>üéØ High-Yield: Supportive Features of DBA</h3>
                        <ul class="feature-list">
                            <li>Elevated erythrocyte deaminase activity</li>
                            <li>Macrocytosis</li>
                            <li>Elevated fetal haemoglobin (HbF)</li>
                            <li>Elevated erythropoietin</li>
                            <li>Family history (8.8% have >1 affected member)</li>
                            <li>Most AD inheritance pattern</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- DBA Genetics Table -->
            <h3 class="subsection-title">Table 30.8: Genetic Subtypes of DBA</h3>
            <div class="callout callout-info">
                <div class="callout-icon">üí°</div>
                <div class="callout-content">
                    <h4>Key Insight</h4>
                    <p>DBA is caused by variants in genes encoding <strong>ribosomal proteins</strong> of both small (RPS) and large (RPL) subunits. This establishes DBA as a <strong>ribosomopathy</strong>, linking it to SDS and 5q- syndrome.</p>
                </div>
            </div>

            <div class="table-responsive">
                <table class="data-table genetics-table">
                    <thead>
                        <tr>
                            <th>DBA Subtype</th>
                            <th>% of Patients</th>
                            <th>Chromosome</th>
                            <th>Protein</th>
                            <th>Notes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="highlight-row">
                            <td><strong>AD (RPS19)</strong></td>
                            <td>25%</td>
                            <td>19q13.2</td>
                            <td>RPS19</td>
                            <td>First gene identified (1999), most common</td>
                        </tr>
                        <tr>
                            <td>AD (Various)</td>
                            <td>10-20%</td>
                            <td>Various</td>
                            <td>Various</td>
                            <td>Large deletions in different DBA genes</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>7%</td>
                            <td>1p22.1</td>
                            <td>RPL5</td>
                            <td>Associated with cleft palate</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>7%</td>
                            <td>12q13.2</td>
                            <td>RPS26</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>5%</td>
                            <td>1p36.11</td>
                            <td>RPL11</td>
                            <td>Associated with thumb malformations</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>3%</td>
                            <td>3q29</td>
                            <td>RPL35A</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>3%</td>
                            <td>6q21.31</td>
                            <td>RPS10</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>X-linked recessive</td>
                            <td>&lt;1%</td>
                            <td>Xp11.23</td>
                            <td>GATA1</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>X-linked recessive</td>
                            <td>&lt;1%</td>
                            <td>Xp11.22</td>
                            <td>TSR2</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>Uncharacterised</td>
                            <td>~25%</td>
                            <td>?</td>
                            <td>?</td>
                            <td>Gene not yet identified</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <!-- Ribosome Biogenesis Diagram -->
            <h3 class="subsection-title">Ribosome Biogenesis and BMF Syndromes</h3>
            <div class="ribosome-diagram">
                <div class="ribosome-pathway">
                    <div class="pathway-stage">
                        <div class="stage-box dna-box">
                            <h4>Ribosomal DNA</h4>
                            <p>45S rRNA transcription</p>
                        </div>
                    </div>
                    <div class="pathway-arrow-down">‚Üì</div>
                    <div class="pathway-stage split-stage">
                        <div class="stage-box small-subunit">
                            <h4>40S Subunit</h4>
                            <p>18S rRNA</p>
                            <div class="affected-genes">
                                <span class="gene-label">DBA genes:</span>
                                <span class="gene-tag small">RPS19</span>
                                <span class="gene-tag small">RPS24</span>
                                <span class="gene-tag small">RPS17</span>
                                <span class="gene-tag small">RPS10</span>
                                <span class="gene-tag small">RPS26</span>
                            </div>
                        </div>
                        <div class="stage-box large-subunit">
                            <h4>60S Subunit</h4>
                            <p>5.8S + 28S + 5S rRNA</p>
                            <div class="affected-genes">
                                <span class="gene-label">DBA genes:</span>
                                <span class="gene-tag small">RPL5</span>
                                <span class="gene-tag small">RPL11</span>
                                <span class="gene-tag small">RPL35A</span>
                                <span class="gene-tag small">RPL26</span>
                            </div>
                            <div class="affected-genes">
                                <span class="gene-label">SDS:</span>
                                <span class="gene-tag small warning">SBDS</span>
                            </div>
                        </div>
                    </div>
                    <div class="pathway-arrow-down">‚Üì</div>
                    <div class="pathway-stage">
                        <div class="stage-box ribosome-final">
                            <h4>80S Ribosome</h4>
                            <p>Functional ribosome for protein synthesis</p>
                        </div>
                    </div>
                </div>
                <div class="ribosome-note">
                    <p><strong>5q- Syndrome Connection:</strong> Haploinsufficiency of <em>RPS14</em> is associated with 5q- syndrome (acquired MDS), demonstrating the link between rare syndromes and common diseases.</p>
                </div>
            </div>

            <!-- DBA Treatment -->
            <div class="treatment-box full-width">
                <h3>Treatment Algorithm for DBA</h3>
                <div class="algorithm-flow">
                    <div class="flow-step">
                        <div class="flow-box primary">
                            <h4>First Line: Corticosteroids</h4>
                            <ul>
                                <li>Prednisolone - standard treatment</li>
                                <li>Once maximal Hb achieved, taper to lowest dose on alternate days</li>
                                <li>79% initially responsive</li>
                            </ul>
                        </div>
                    </div>
                    <div class="flow-arrow">‚Üì</div>
                    <div class="flow-branch">
                        <div class="flow-box success">
                            <h4>Steroid Responsive</h4>
                            <p>Maintain on lowest effective dose</p>
                            <p>Some achieve spontaneous remission</p>
                        </div>
                        <div class="flow-box warning">
                            <h4>Steroid Refractory/Dependent</h4>
                            <ul>
                                <li>Regular transfusions</li>
                                <li>Iron chelation (deferiprone preferred)</li>
                                <li>Consider HSCT if HLA-matched donor</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="callout callout-warning">
                <div class="callout-icon">‚ö†Ô∏è</div>
                <div class="callout-content">
                    <h4>Important: Evolution of DBA</h4>
                    <p>Although DBA classically presents as pure red cell aplasia, there is evidence for a <strong>trilineage haemopoietic defect</strong> in patients with refractory DBA. Neutropenia and thrombocytopenia are relatively common after the first decade. MDS and AML have been reported in a few patients.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- CDA Section -->
    <section id="cda" class="section section-alt">
        <div class="container">
            <h2 class="section-title">Congenital Dyserythropoietic Anaemia (CDA)</h2>

            <div class="callout callout-key">
                <div class="callout-icon">üîë</div>
                <div class="callout-content">
                    <h4>Definition</h4>
                    <p>CDA comprises a heterogeneous group of disorders of erythropoiesis characterized by <strong>anaemia</strong>, <strong>ineffective erythropoiesis</strong>, and frequently <strong>morphological evidence of dyserythropoiesis</strong>.</p>
                </div>
            </div>

            <!-- CDA Types Comparison -->
            <h3 class="subsection-title">Table 30.9: Characteristics of CDA Types</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Feature</th>
                            <th>Type I</th>
                            <th>Type II (HEMPAS)</th>
                            <th>Type III</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Inheritance</strong></td>
                            <td>AR</td>
                            <td>AR</td>
                            <td>AD</td>
                        </tr>
                        <tr>
                            <td><strong>Erythrocytes</strong></td>
                            <td>Macrocytic</td>
                            <td>Normocytic</td>
                            <td>Macrocytic</td>
                        </tr>
                        <tr>
                            <td><strong>Erythroblasts - Light microscopy</strong></td>
                            <td>Megaloblastic, internuclear chromatin bridges</td>
                            <td>Normoblastic, binuclearity</td>
                            <td>Megaloblastic, up to 12 nuclei/cell</td>
                        </tr>
                        <tr>
                            <td><strong>Electron microscopy</strong></td>
                            <td>'Swiss-cheese' appearance of heterochromatin</td>
                            <td>Peripheral double membranes</td>
                            <td>Non-specific</td>
                        </tr>
                        <tr>
                            <td><strong>Ham test</strong></td>
                            <td>Negative</td>
                            <td>Usually positive</td>
                            <td>Negative</td>
                        </tr>
                        <tr>
                            <td><strong>Anti-i agglutinability</strong></td>
                            <td>Normal/strong</td>
                            <td>Strong</td>
                            <td>Normal/strong</td>
                        </tr>
                        <tr>
                            <td><strong>SDS-PAGE</strong></td>
                            <td>Normal</td>
                            <td>Band 3 thinner, migrates faster than normal</td>
                            <td>Band 3 migrates faster than normal</td>
                        </tr>
                        <tr class="highlight-row">
                            <td><strong>Genes identified</strong></td>
                            <td>CDAN1 (15q15.2), CDIN1 (15q14)</td>
                            <td>SEC23B (20p11.23)</td>
                            <td>KIF23 (15q23)</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="cda-cards">
                <div class="cda-card type-1">
                    <h3>CDA Type I</h3>
                    <div class="cda-features">
                        <p><strong>Presentation:</strong> Splenomegaly, mild-moderate anaemia (~66-116 g/L), ~70% macrocytosis</p>
                        <p><strong>BM:</strong> Megaloblastic erythroid hyperplasia with internuclear chromatin bridging</p>
                        <p><strong>EM:</strong> 'Swiss cheese' appearance of heterochromatin</p>
                        <p><strong>Treatment:</strong> Interferon-Œ± may improve Hb in some cases</p>
                    </div>
                </div>
                <div class="cda-card type-2">
                    <h3>CDA Type II (HEMPAS)</h3>
                    <div class="cda-features">
                        <p><strong>Most common subtype</strong></p>
                        <p><strong>Presentation:</strong> Variable anaemia (80-110 g/L), ~10% require regular transfusions</p>
                        <p><strong>BM:</strong> Normoblastic hyperplasia with binucleate/multinucleate erythroblasts</p>
                        <p><strong>EM:</strong> Peripheral double membrane arrangement</p>
                        <p><strong>Treatment:</strong> Iron chelation essential; splenectomy may help; HSCT for severe cases</p>
                    </div>
                </div>
                <div class="cda-card type-3">
                    <h3>CDA Type III</h3>
                    <div class="cda-features">
                        <p><strong>Rarest subtype</strong></p>
                        <p><strong>Presentation:</strong> Giant multinucleated erythroblasts in marrow (up to 12 nuclei)</p>
                        <p><strong>Caused by:</strong> Variants in <em>KIF23</em> - encodes mitotic kinesin-like protein 1 (cytokinesis)</p>
                        <p><strong>Treatment:</strong> Mild anaemia - usually no major intervention needed; folate supplementation</p>
                    </div>
                </div>
            </div>

            <div class="callout callout-exam">
                <div class="callout-icon">üìù</div>
                <div class="callout-content">
                    <h4>Exam Pearl: HEMPAS</h4>
                    <p>CDA Type II is also called <strong>HEMPAS</strong> (Hereditary Erythroblastic Multinuclearity with Positive Acidified Serum test). The positive Ham test (acidified serum lysis) distinguishes it from PNH - in CDA II, red cells are lysed by some acidified sera but NOT by the patient's own serum.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Congenital Neutropenia Section -->
    <section id="neutropenia" class="section">
        <div class="container">
            <h2 class="section-title">Congenital and Cyclical Neutropenias</h2>

            <div class="callout callout-key">
                <div class="callout-icon">üîë</div>
                <div class="callout-content">
                    <h4>Overview</h4>
                    <p>Congenital neutropenia is a heterogeneous disorder including <strong>Kostmann syndrome</strong> (first described 1954). The neutropenia is usually recognized at birth with <strong>ANC often below 0.2 √ó 10‚Åπ/L</strong>. Associated with severe infections and early death without treatment.</p>
                </div>
            </div>

            <div class="two-column">
                <div class="column">
                    <div class="info-box">
                        <h3>Severe Congenital Neutropenia (SCN)</h3>
                        <ul class="check-list">
                            <li>ANC usually &lt;0.2 √ó 10‚Åπ/L</li>
                            <li>Hb and platelets usually normal</li>
                            <li>BM: Maturation arrest at promyelocyte/myelocyte stage</li>
                            <li>Abundant promyelocytes, reduced neutrophils</li>
                            <li>Severe infections without treatment</li>
                            <li>~25% develop myeloid leukaemia by 25 years</li>
                            <li>No patients have developed AA</li>
                        </ul>
                    </div>
                </div>
                <div class="column">
                    <div class="info-box">
                        <h3>Cyclical Neutropenia</h3>
                        <ul class="check-list">
                            <li>Neutrophil count cycles with ~21-day periodicity</li>
                            <li>ANC reaches nadir (may be zero)</li>
                            <li>Fever and mouth ulcers at nadir</li>
                            <li>Usually AD inheritance</li>
                            <li>Also caused by <em>ELANE</em> mutations</li>
                            <li>Variants cluster at different site than SCN</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- Neutropenia Genetics -->
            <h3 class="subsection-title">Table 30.10: Genetic Subtypes of Neutropenia</h3>
            <div class="table-responsive">
                <table class="data-table genetics-table">
                    <thead>
                        <tr>
                            <th>Subtype</th>
                            <th>% of Patients</th>
                            <th>Chromosome</th>
                            <th>Gene/Protein</th>
                            <th>Key Features</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="subtype-header">
                            <td colspan="5"><strong>Autosomal Dominant</strong></td>
                        </tr>
                        <tr class="highlight-row">
                            <td>SCN/Cyclical</td>
                            <td>50-60%</td>
                            <td>19p13.3</td>
                            <td>ELANE (neutrophil elastase)</td>
                            <td>Most common cause; UPR activation</td>
                        </tr>
                        <tr>
                            <td>SCN</td>
                            <td>&lt;2%</td>
                            <td>1p22.1</td>
                            <td>GFI1</td>
                            <td>Transcription factor</td>
                        </tr>
                        <tr class="subtype-header">
                            <td colspan="5"><strong>Autosomal Recessive</strong></td>
                        </tr>
                        <tr>
                            <td>SCN (Kostmann)</td>
                            <td>10-15%</td>
                            <td>1q21.3</td>
                            <td>HAX1</td>
                            <td>Original Kostmann families; mitochondrial apoptosis</td>
                        </tr>
                        <tr>
                            <td>SCN</td>
                            <td>~5%</td>
                            <td>17q21.31</td>
                            <td>G6PC3</td>
                            <td>Associated with cardiac/urogenital defects</td>
                        </tr>
                        <tr>
                            <td>SCN</td>
                            <td>Rare</td>
                            <td>1q21.2</td>
                            <td>VPS45</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>SCN</td>
                            <td>Rare</td>
                            <td>1p34.3</td>
                            <td>CSF3R</td>
                            <td>G-CSF receptor</td>
                        </tr>
                        <tr>
                            <td>SCN</td>
                            <td>Rare</td>
                            <td>3p25.3</td>
                            <td>JAGN1</td>
                            <td></td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="callout callout-info">
                <div class="callout-icon">üí°</div>
                <div class="callout-content">
                    <h4>Molecular Insight: ELANE Mutations</h4>
                    <p><em>ELANE</em> encodes neutrophil elastase, a serine protease synthesized predominantly at the promyelocytic stage. Variants lead to accumulation of <strong>non-functional protein</strong> which triggers the <strong>unfolded protein response (UPR)</strong> leading to maturational arrest and apoptosis.</p>
                </div>
            </div>

            <!-- Treatment -->
            <div class="treatment-box">
                <h3>Treatment of Congenital Neutropenia</h3>
                <div class="treatment-grid">
                    <div class="treatment-item">
                        <h4>üíâ G-CSF</h4>
                        <ul>
                            <li>Revolutionized outcomes for these patients</li>
                            <li>Improves neutrophil counts</li>
                            <li>Reduces infections</li>
                            <li>Monitor for G-CSF receptor mutations</li>
                        </ul>
                    </div>
                    <div class="treatment-item">
                        <h4>üè• HSCT</h4>
                        <ul>
                            <li>For G-CSF refractory patients</li>
                            <li>For those who develop leukaemia</li>
                            <li>Curative option</li>
                        </ul>
                    </div>
                    <div class="treatment-item">
                        <h4>‚ö†Ô∏è Leukaemia Risk</h4>
                        <ul>
                            <li>~25% develop myeloid leukaemia by 25 years</li>
                            <li>G-CSF receptor mutations may contribute</li>
                            <li>Regular BM surveillance</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <!-- Thrombocytopenia Syndromes -->
    <section id="thrombocytopenia" class="section section-alt">
        <div class="container">
            <h2 class="section-title">Congenital Thrombocytopenias: CAMT & TAR</h2>

            <div class="two-column">
                <div class="column">
                    <div class="syndrome-card">
                        <h3>CAMT (Congenital Amegakaryocytic Thrombocytopenia)</h3>
                        <div class="syndrome-content">
                            <p><strong>Presentation:</strong> Infancy with isolated thrombocytopenia, reduction/absence of megakaryocytes in BM, no somatic abnormalities</p>
                            <p><strong>Evolution:</strong> ~50% develop AA usually by age 5 years</p>
                            <p><strong>Genetics:</strong> Biallelic variants in <em>MPL</em> (thrombopoietin receptor) - 1p34</p>
                            <p><strong>Lab:</strong> Elevated TPO levels, normal leucocyte and Hb</p>
                            <p><strong>Treatment:</strong> HSCT if compatible donor; platelet transfusions for severe bleeding</p>
                        </div>
                    </div>
                </div>
                <div class="column">
                    <div class="syndrome-card">
                        <h3>TAR (Thrombocytopenia with Absent Radii)</h3>
                        <div class="syndrome-content">
                            <p><strong>Presentation:</strong> Hypomegakaryocytic thrombocytopenia + bilateral radial aplasia at birth</p>
                            <p><strong>Key Feature:</strong> <em>Thumbs are present</em> (distinguishes from FA)</p>
                            <p><strong>Other features:</strong> Absent ulnae, absent humeri, clinodactyly, microcephaly</p>
                            <p><strong>Genetics:</strong> Compound heterozygosity - deletion + regulatory SNP in <em>RBM8A</em></p>
                            <p><strong>Prognosis:</strong> Platelet count usually improves after first year; good prognosis with supportive care</p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- CAMT vs TAR Comparison -->
            <h3 class="subsection-title">Table 30.11: Genetic Subtypes of Syndromic Thrombocytopenias</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Subtype</th>
                            <th>% of Patients</th>
                            <th>Chromosome</th>
                            <th>Gene</th>
                            <th>Key Features</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="highlight-row">
                            <td>CAMT AR</td>
                            <td>Majority</td>
                            <td>1p34</td>
                            <td>MPL</td>
                            <td>TPO receptor; progresses to AA</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>TAR AR</td>
                            <td>Majority</td>
                            <td>1q21.1</td>
                            <td>RBM8A</td>
                            <td>Radial aplasia + thumbs present</td>
                        </tr>
                        <tr>
                            <td>Radio-ulnar synostosis AD</td>
                            <td>Major subset</td>
                            <td>7p15.2</td>
                            <td>HOXA11</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>Major subset</td>
                            <td>3q26.2</td>
                            <td>MECOM*</td>
                            <td>Variable features from thrombocytopenia to global BMF</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="callout callout-exam">
                <div class="callout-icon">üìù</div>
                <div class="callout-content">
                    <h4>Exam Pearl: TAR vs Fanconi Anaemia</h4>
                    <p>Both TAR and FA can present with radial abnormalities. The key distinguishing feature: in <strong>TAR, thumbs are PRESENT</strong> despite absent radii. In <strong>FA, thumbs may be absent or hypoplastic</strong>. Also, TAR patients have normal chromosome breakage studies.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Diagnostic Algorithm Section -->
    <section id="diagnosis" class="section">
        <div class="container">
            <h2 class="section-title">Diagnostic Approach to Inherited BMF</h2>

            <div class="callout callout-clinical">
                <div class="callout-icon">üè•</div>
                <div class="callout-content">
                    <h4>Clinical Clues Suggesting Inherited BMF</h4>
                    <ul class="inline-list">
                        <li>Young age at presentation</li>
                        <li>Family history of cytopenias/MDS/AML</li>
                        <li>Somatic abnormalities</li>
                        <li>Single cytopenia progressing to pancytopenia</li>
                        <li>Poor response to immunosuppressive therapy</li>
                        <li>Unexpected toxicity from chemotherapy/radiation</li>
                    </ul>
                </div>
            </div>

            <!-- Diagnostic Algorithm -->
            <h3 class="subsection-title">Diagnostic Algorithm</h3>
            <div class="algorithm-container">
                <div class="algorithm-flowchart">
                    <div class="flow-node start">
                        <span>Suspected Inherited BMF</span>
                    </div>
                    <div class="flow-arrow-down">‚Üì</div>
                    <div class="flow-node">
                        <h4>Initial Evaluation</h4>
                        <ul>
                            <li>Complete history including family</li>
                            <li>Physical exam for somatic abnormalities</li>
                            <li>CBC, reticulocytes, blood film</li>
                            <li>BM aspirate and biopsy</li>
                        </ul>
                    </div>
                    <div class="flow-arrow-down">‚Üì</div>
                    <div class="flow-node">
                        <h4>Specialized Testing</h4>
                        <ul>
                            <li>DEB/MMC chromosome breakage test (FA)</li>
                            <li>Telomere length (DC)</li>
                            <li>Fetal haemoglobin (DBA)</li>
                            <li>Erythrocyte adenosine deaminase (DBA)</li>
                        </ul>
                    </div>
                    <div class="flow-arrow-down">‚Üì</div>
                    <div class="flow-node">
                        <h4>Genetic Testing</h4>
                        <ul>
                            <li>NGS gene panels (FA, DC, DBA, SDS, etc.)</li>
                            <li>Whole exome/genome if panel negative</li>
                            <li>Confirm with Sanger sequencing</li>
                        </ul>
                    </div>
                    <div class="flow-arrow-down">‚Üì</div>
                    <div class="flow-node end">
                        <span>Diagnosis ‚Üí Management ‚Üí Family Counseling</span>
                    </div>
                </div>
            </div>

            <!-- Laboratory Tests Table -->
            <h3 class="subsection-title">Table 30.13: Laboratory Tests in BMF Investigation</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Test</th>
                            <th>Diagnostic Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="category-header">
                            <td colspan="2"><strong>Peripheral Blood</strong></td>
                        </tr>
                        <tr>
                            <td>Fetal haemoglobin</td>
                            <td>High level suggestive of generalised BMF</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>DEB/MMC-induced chromosomal breakage</td>
                            <td><strong>Increased in FA</strong></td>
                        </tr>
                        <tr class="category-header">
                            <td colspan="2"><strong>Genetic Analysis (NGS)</strong></td>
                        </tr>
                        <tr>
                            <td>FANCA-FANCW</td>
                            <td>Mutated in FA</td>
                        </tr>
                        <tr>
                            <td>DKC1, TERC, TERT, NOP10, NHP2, TIN2, etc.</td>
                            <td>Mutated in DC and related disorders</td>
                        </tr>
                        <tr>
                            <td>SBDS, DNAJC21, EFL1, SRP54</td>
                            <td>Mutated in SDS and SDS-like disease</td>
                        </tr>
                        <tr>
                            <td>RPS/RPL genes</td>
                            <td>Mutated in DBA and DBA-like disease</td>
                        </tr>
                        <tr>
                            <td>ELANE, HAX1, GFI1, G6PC3, etc.</td>
                            <td>Mutated in congenital and cyclic neutropenia</td>
                        </tr>
                        <tr>
                            <td>MPL, RBM8A, HOXA11, MECOM</td>
                            <td>Mutated in CAMT and other syndromic thrombocytopenias</td>
                        </tr>
                        <tr class="category-header">
                            <td colspan="2"><strong>Other Investigations</strong></td>
                        </tr>
                        <tr>
                            <td>Mitochondrial DNA analysis</td>
                            <td>Deletions seen in Pearson syndrome</td>
                        </tr>
                        <tr>
                            <td>X-chromosome inactivation patterns</td>
                            <td>Skewed in carriers of X-linked DC</td>
                        </tr>
                        <tr>
                            <td>Ham test (CD59 analysis now preferred)</td>
                            <td>Positive in PNH (distinguish from CDA II)</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>Telomere length</td>
                            <td><strong>Short in AA, very short in DC</strong></td>
                        </tr>
                        <tr>
                            <td>Constitutional karyotype</td>
                            <td>Abnormality suggestive of constitutional AA</td>
                        </tr>
                        <tr class="category-header">
                            <td colspan="2"><strong>Somatic Abnormality Assessment</strong></td>
                        </tr>
                        <tr>
                            <td>Skeletal survey, renal US, PFTs, Echo</td>
                            <td>Presence with AA suggestive of inherited BMF</td>
                        </tr>
                        <tr>
                            <td>Exocrine pancreatic function</td>
                            <td>Abnormal in SDS and Pearson syndrome</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>
    </section>

    <!-- New BMF Subtypes Section -->
    <section id="new-subtypes" class="section section-alt">
        <div class="container">
            <h2 class="section-title">New BMF Subtypes & Overlapping Syndromes</h2>

            <div class="callout callout-info">
                <div class="callout-icon">üî¨</div>
                <div class="callout-content">
                    <h4>Emerging Understanding</h4>
                    <p>NGS has enabled identification of cases with germline variants that don't fit traditional categories. These include genes associated with familial MDS/AML (RUNX1, CEBPA, GATA2, DDX41) and others producing variable extra-haematopoietic abnormalities.</p>
                </div>
            </div>

            <h3 class="subsection-title">Table 30.12: New BMF and Overlapping Syndromes</h3>
            <div class="table-responsive">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Category</th>
                            <th>Gene</th>
                            <th>Chromosome</th>
                            <th>Key Features</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="subtype-header">
                            <td colspan="4"><strong>Recently Recognised BMF Subtypes (AR)</strong></td>
                        </tr>
                        <tr>
                            <td>AR</td>
                            <td>ERCC6L2</td>
                            <td>9q22.32</td>
                            <td>DNA repair</td>
                        </tr>
                        <tr>
                            <td>AR</td>
                            <td>TPO/THPO</td>
                            <td>3q27.1</td>
                            <td>Thrombopoietin deficiency</td>
                        </tr>
                        <tr>
                            <td>AR</td>
                            <td>MYSM1</td>
                            <td>1p32.1</td>
                            <td>Histone deubiquitinase</td>
                        </tr>
                        <tr class="subtype-header">
                            <td colspan="4"><strong>Familial MDS/Leukaemia (AD)</strong></td>
                        </tr>
                        <tr class="highlight-row">
                            <td>AD</td>
                            <td>RUNX1</td>
                            <td>21q22.12</td>
                            <td>Familial platelet disorder ‚Üí AML</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>CEBPA</td>
                            <td>19q13.11</td>
                            <td>Familial AML</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>AD</td>
                            <td>GATA2</td>
                            <td>3q21.3</td>
                            <td>MonoMAC syndrome; immunodeficiency + MDS</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>SRP72</td>
                            <td>4q12</td>
                            <td></td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>ANKRD26</td>
                            <td>10p12.1</td>
                            <td>Thrombocytopenia ‚Üí MDS/AML</td>
                        </tr>
                        <tr class="highlight-row">
                            <td>AD</td>
                            <td>DDX41</td>
                            <td>5q35.3</td>
                            <td>Late-onset familial MDS/AML</td>
                        </tr>
                        <tr>
                            <td>AD</td>
                            <td>ETV6</td>
                            <td>12p13.2</td>
                            <td>Thrombocytopenia + leukaemia predisposition</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="callout callout-warning">
                <div class="callout-icon">‚ö†Ô∏è</div>
                <div class="callout-content">
                    <h4>Clinical Importance of GATA2 Deficiency</h4>
                    <p><strong>GATA2</strong> deficiency can be associated with: pulmonary alveolar proteinosis, primary lymphoedema, SAMD9 disease with adrenal insufficiency, intrauterine growth restriction and genital abnormalities, SAMD9L disease with neurologic/cerebellar/ophthalmic abnormalities.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Summary Section -->
    <section id="summary" class="section">
        <div class="container">
            <h2 class="section-title">Key Takeaways</h2>

            <div class="summary-grid">
                <div class="summary-card">
                    <div class="summary-icon">üß¨</div>
                    <h3>Fanconi Anaemia</h3>
                    <ul>
                        <li>DNA repair defect (FA-BRCA pathway)</li>
                        <li>22 genes; A, C, G most common</li>
                        <li>DEB/MMC test diagnostic</li>
                        <li>High malignancy risk</li>
                        <li>Modified HSCT conditioning essential</li>
                    </ul>
                </div>
                <div class="summary-card">
                    <div class="summary-icon">üî¨</div>
                    <h3>Dyskeratosis Congenita</h3>
                    <ul>
                        <li>Telomere biology disorder</li>
                        <li>Mucocutaneous triad</li>
                        <li>20 genes; DKC1, TERC, TERT key</li>
                        <li>Very short telomeres diagnostic</li>
                        <li>Pulmonary disease major cause of death</li>
                    </ul>
                </div>
                <div class="summary-card">
                    <div class="summary-icon">ü¶¥</div>
                    <h3>Shwachman-Diamond</h3>
                    <ul>
                        <li>Ribosome biogenesis defect</li>
                        <li>SBDS gene (>90%)</li>
                        <li>Pancreatic insufficiency + BMF</li>
                        <li>Pancreatic enzymes + G-CSF</li>
                        <li>~25% develop MDS/AML</li>
                    </ul>
                </div>
                <div class="summary-card">
                    <div class="summary-icon">üî¥</div>
                    <h3>Diamond-Blackfan Anaemia</h3>
                    <ul>
                        <li>Ribosomopathy</li>
                        <li>RPS19 most common (25%)</li>
                        <li>Pure red cell aplasia</li>
                        <li>Corticosteroids first line</li>
                        <li>Elevated HbF and eADA supportive</li>
                    </ul>
                </div>
                <div class="summary-card">
                    <div class="summary-icon">‚ö™</div>
                    <h3>Congenital Neutropenia</h3>
                    <ul>
                        <li>ELANE most common (50-60%)</li>
                        <li>Maturational arrest at promyelocyte</li>
                        <li>G-CSF revolutionized outcomes</li>
                        <li>~25% leukaemia risk by 25 years</li>
                        <li>HSCT for refractory cases</li>
                    </ul>
                </div>
                <div class="summary-card">
                    <div class="summary-icon">ü©∏</div>
                    <h3>Syndromic Thrombocytopenias</h3>
                    <ul>
                        <li>CAMT: MPL mutations ‚Üí AA</li>
                        <li>TAR: RBM8A; thumbs present</li>
                        <li>Distinguish TAR from FA</li>
                        <li>HSCT for severe CAMT</li>
                        <li>TAR often improves with age</li>
                    </ul>
                </div>
            </div>

            <div class="conclusion-box">
                <h3>Conclusion</h3>
                <p>Since identification of the first FA gene (FANCC) in 1992, there have been significant advances in understanding FA, DC, and other BMF syndromes. This has facilitated diagnosis and highlighted the importance of studying rare syndromes for insights into common diseases. The connection between:</p>
                <ul>
                    <li><strong>DC and AA</strong> - via defective telomere maintenance</li>
                    <li><strong>DBA, SDS, and MDS</strong> - via defective ribosome biogenesis</li>
                </ul>
                <p>These advances suggest that new treatment strategies targeting primary defects in each syndrome are likely to emerge.</p>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <div class="footer-content">
                <div class="footer-brand">
                    <span class="logo">Blood<span class="blood-drop">ü©∏</span>Doctor</span>
                    <p>Making haematology education accessible</p>
                </div>
                <div class="footer-info">
                    <p><strong>Dr Abdul Mannan</strong><br>FRCPath, FCPS</p>
                    <p><a href="mailto:blooddoctor.co@gmail.com">blooddoctor.co@gmail.com</a></p>
                </div>
                <div class="footer-source">
                    <p>Based on: <strong>Hoffbrand's Postgraduate Haematology, 8th Edition</strong></p>
                    <p>Chapter 30: Inherited Aplastic Anaemia/Bone Marrow Failure Syndromes</p>
                    <p>Author: Inderjeet S Dokal</p>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2025 Bloodü©∏Doctor. Educational purposes only.</p>
                <p>#BloodDoctor</p>
            </div>
        </div>
    </footer>

    <!-- Back to Top -->
    <button class="back-to-top" aria-label="Back to top">‚Üë</button>

    <script src="script.js"></script>
</body>
</html>
